新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%_老虎社区_美港股上老虎

新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%

老虎资讯综合05-27

派格生物医药-B 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。

生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

改名牛牛
·05-27
有绿鞋吗？
回复
1
举报
收起
- 顾坦山__Luke_:
  没
  05-27
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1146090593?lang=zh_CN&edition=full","thumbnail":"https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0","is_english":false,"pubTime":"2025-05-27 08:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146090593","market":"hk","top_or_hot":-1,"title":"新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%","media":"老虎资讯综合","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">派格生物医药-B</a> 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。</p><p>生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/14919fe317e1073f15300b43d0cb3e67\" title=\"\" tg-width=\"517\" tg-height=\"667\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/4008039a96c622d2ecb45687a7e5abce\" title=\"\" tg-width=\"514\" tg-height=\"622\"/></p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-05-27 08:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">派格生物医药-B</a> 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。</p><p>生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/14919fe317e1073f15300b43d0cb3e67\" title=\"\" tg-width=\"517\" tg-height=\"667\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/4008039a96c622d2ecb45687a7e5abce\" title=\"\" tg-width=\"514\" tg-height=\"622\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1146090593","we_media_id":"102","thumbnails":["https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146090593","pubTimestamp":1748304305,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":" $派格生物医药-B(02565)$ 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元元。股份预期周二(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"Pricing of new shares Paige Biomedical is priced at HK $15.6 per share, and the public offering was subscribed 743.78 times, with a winning rate of 8%.","themeId":"9def1a2fcaf9e5fd93e233e38a747185","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/1a27652253e2ed3225dc5a80b79be61e","symbols_score_info":{"02565":1.1},"content_text":"派格生物医药-B 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":439464448659512,"gmtCreate":1748309966132,"gmtModify":1748309968105,"author":{"id":"3443677141101234","authorId":"3443677141101234","name":"改名牛牛","avatar":"https://static.tigerbbs.com/783ce3e2d6e257c1281d14b29514a2fb","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3443677141101234","authorIdStr":"3443677141101234"},"htmlText":"有绿鞋吗？","listText":"有绿鞋吗？","text":"有绿鞋吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/439464448659512","repostId":1146090593,"repostType":2,"repost":{"id":"1146090593","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1748304305,"share":"https://www.laohu8.com/m/news/1146090593?lang=&edition=full","pubTime":"2025-05-27 08:05","market":"hk","language":"zh","title":"新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146090593","media":"老虎资讯综合","summary":" $派格生物医药-B(02565)$ 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元元。股份预期周二(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">派格生物医药-B</a> 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。</p><p>生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/14919fe317e1073f15300b43d0cb3e67\" title=\"\" tg-width=\"517\" tg-height=\"667\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/4008039a96c622d2ecb45687a7e5abce\" title=\"\" tg-width=\"514\" tg-height=\"622\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-05-27 08:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">派格生物医药-B</a> 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。</p><p>生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/14919fe317e1073f15300b43d0cb3e67\" title=\"\" tg-width=\"517\" tg-height=\"667\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/4008039a96c622d2ecb45687a7e5abce\" title=\"\" tg-width=\"514\" tg-height=\"622\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0","relate_stocks":{"02565":"派格生物医药-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146090593","content_text":"派格生物医药-B 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":439466775400904,"gmtCreate":1748310119804,"gmtModify":1748314927514,"authorId":3578553421027370,"author":{"id":3578553421027370,"idStr":"3578553421027370","authorId":3578553421027370,"name":"顾坦山__Luke_","avatar":"https://static.tigerbbs.com/d1da66f052b8b61135171d9e6faffa72","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":439464448659512,"type":1,"supId":0,"prevId":0,"content":"没","text":"没","html":"没"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}